Posted by Michael Wonder on 26 Dec 2021
Pfizer and BioNTech submit updated longer-term follow-up data of Comirnaty in adolescents 12 through 15 years of age to EMA
23 December 2021 - Pfizer and BioNTech today announced that they have submitted longer-term follow-up data from the companies’ pivotal Phase 3 clinical trial in 2,228 individuals 12 through 15 years of age to the EMA to further support the favourable safety and efficacy profile of Comirnaty (COVID-19 mRNA vaccine) in this age group.
In the trial, a two dose series of Comirnaty (30 mcg per dose) was 100% effective (95%CI [CI, 87.5, 100.0]) against COVID-19, measured seven days through over four months after the second dose.
